NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a ...

Keros Therapeutics Inc (KROS) stock saw a decline, ending the day at $11.39 which represents a decrease of $-0.02 or -0.18% from the prior close of $11.41. The stock opened at $11.31 and touched a low ...

Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its target price cut by equities research analysts at Oppenheimer from ...

Oppenheimer has recently reiterated Keros Therapeutics Inc (KROS) stock to Outperform rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 16, 2024, Guggenheim had ...

Keros Therapeutics (NASDAQ:KROS – Free Report) had its price target lowered by Piper Sandler from $40.00 to $15.00 in a research report report published on Friday,Benzinga reports. The firm currently ...

Investing.com -- Keros Therapeutics, Inc. (NASDAQ: KROS) shares rose 6% following the announcement of the effectiveness of its global license agreement with pharmaceutical giant Takeda. The deal, ...

Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing ...